AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02313597 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SETON
Description: In seton treatment, initially Hydrogen peroxide will be applied to the external opening with a 10-cc syringe, and the internal opening will be located by direct visualization of the anal canal via proctoscope. A probe will be inserted into the external opening and carefully maneuvered through the internal opening. Silk 1/0 suture will be then tied to the tip of the probe, which will be then squeezed out of the external opening. The suture will be then tied around the sphincter and through fistula tract. Later, the seton will be tightened at four-week intervals under local anesthesia until the suture cut through the sphincter.
Study NCT02313597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VAAFT
Description: Patients assigned to the VAAFT group will receive the following procedure. The external opening will be widened with a probe, and a fistulascope will be inserted to delineate the primary and secondary tracts and locate the internal opening. The internal opening will be then stitched with Vicryl™ (Polyglactin 910) 2-0 suture through the anal route with the help of a proctoscope. The tract of the fistula will be washed and debrided through the scope and cauterized. Finally, the external opening will be excised and will be sent for biopsy.
Study NCT02373930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Study NCT02373930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Study NCT02373930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Study NCT02373930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Study NCT01264471 — intervention group
Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
Study NCT01264471 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Collection
Description: Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.
Study NCT02237274 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High altitude exposition
Description: High altitude exposition
Study NCT02237274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High altitude exposition
Description: High altitude exposition
Study NCT00448357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabbit anti-thymocyte globulin (ATG)
Description: .5 mg/kg on day -3 and 2.5 mg/kg on day -2
Study NCT00448357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: minimum total cluster of differentiation (CD34+) cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0
Study NCT00448357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: PK-targeted continuous IV infusion over 90 hours on Days -7 to -4.
Study NCT00448357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 30 mg/m\^2/day x 5 days intravenous piggyback (IVPB) over 30 minutes on Days -7 through -3
Study NCT00448357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: The suggested starting dose is 0.03 mg/kg po bid starting on day -1
Study NCT00448357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: A minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and maximum of 8 x 10\^6 cells/kg will be infused on day 0
Study NCT00448357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0
Study NCT00448357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 5 mg/m\^2 on days +1, +3 and +6
Study NCT03470766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nevro Senza System (HF10 Therapy)
Description: Nevro 10kHz High Frequency Spinal Cord Stimulation
Study NCT03470766 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nevro Senza System (HF10 Therapy)
Description: Nevro 10kHz High Frequency Spinal Cord Stimulation
Study NCT02087683 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vitamin D Supplementation
Description: Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologist, whom will give them the vitamin supply for a month.
Study NCT02087683 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Placebo)
Description: Participants in this group will receive a placebo made of gelatin and corn oil per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologists, whom will give the vitamin supply for a month.
Study NCT02373930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AR
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Study NCT03215914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed 670G system
Description: Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels \< 70 mg/dl.
Study NCT03370757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3-hour bundled care
Description: Infants in the 3-hour bundled care group will receive diaper changes every 3 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 3 times per week.
Study NCT03370757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-hour bundled care
Description: Infants in the 6-hour bundled care group will receive diaper changes every 6 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 4 times per week.
Study NCT02014948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: The individuals who make up this group performed exercises for 10 consecutive sessions.
Study NCT04813744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment
Study NCT05726695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: microRNA test
Description: Laboratory analysis for the detection of microRNA in blood samples.
Study NCT05726695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart ultrasound examination
Description: Heart ultrasound examination will be performed as a standard cardiology examination.
Study NCT00508508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response System
Description: Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.
Study NCT00508508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Led Group Clinic Visits
Description: At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.
Study NCT01447771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision control preference scale
Description: At time 1, participants in the intervention group will be asked to complete the Decision Control Preference Scale.The range of decision control is measured by the Decision Control Preference (DCP) Scale. The scale is used to measure the preferred or actual role in decision making using five response statements: two represent an active or patient-controlled role, one a shared or collaborative role, and two represent a passive or provider-controlled role. The preferred level of decision making control will be known by the participant in the intervention group and the information given to the oncologist prior to the consultation regarding adjuvant therapy
Study NCT01773824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antibiotic prescription feedback
Description: Monthly postal and electronic feedback on antibiotic prescription rates
Study NCT01773824 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Feedback
Description: Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial)
Study NCT00702624 — intervention group
Intervention type: DRUG
Intervention: Corifollitropin alfa
Description: Single injection of 100 μg corifollitropin alfa administered under protocol P05690
Study NCT00702624 — intervention group
Intervention type: BIOLOGICAL
Intervention: recFSH (follitropin beta)
Description: Daily recFSH administered under protocol P05690
Study NCT00702624 — intervention group
Intervention type: DRUG
Intervention: gonadatropin releasing hormone (GnRH) antagonist ganirelix
Description: GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
Study NCT00702624 — intervention group
Intervention type: BIOLOGICAL
Intervention: human chorion gonadotropin (hCG)
Description: hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690
Study NCT00702624 — intervention group
Intervention type: BIOLOGICAL
Intervention: progesterone
Description: Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
Study NCT00702624 — intervention group
Intervention type: DRUG
Intervention: placebo-recFSH (follitropin beta)
Description: Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
Study NCT00702624 — intervention group
Intervention type: DRUG
Intervention: placebo-corifollitropin alfa
Description: Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
Study NCT00702624 — intervention group
Intervention type: BIOLOGICAL
Intervention: open-label recFSH (follitropin beta)
Description: Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690
Study NCT04008212 — intervention group
Intervention type: OTHER
Intervention: Fusion imaging
Description: Fusion imaging during aortic endovascular procedures with a mobile C-arm through the use of the EndoNaut® angio-navigation station
Study NCT02988648 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioiodide (131I-)
Description: The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
Study NCT03037216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: 10 Week aerobic exercise training
Study NCT03139370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KITE-718
Description: A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).
Study NCT03139370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study NCT03139370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study NCT03139370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGE - A3/A6 Screening Test
Description: A screening test for MAGE-A3/A6+ tumors
Study NCT03154138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The prismatic adaptation (PA)
Description: Prismatic adaptation (PA) is based on the wearing of a pair of glasses producing a visual field deviation of 10° to rightward. While wearing theses glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements with a shift toward the right side (initial errors consecutive to the prism deviation). Taking into account theses errors, the patient then compensates the optical deviation. After removing the prismatic glasses, the asked pointing movement to the targets is once again shifted but to the left side this time (after-effects attesting the prismatic adaptation)
Study NCT03154138 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The sham prismatic adaptation (S-PA)
Description: The sham prismatic adaptation (S-PA) is based on the wearing of a pair of glasses producing no visual field deviation. Theses sham glasses is identical with theses used in PA group without the optical deviation. The conditions are similar with theses in the PA group.~The procedure with the sham glasses are similar with these one used in the PA group: While wearing the sham glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The support with targets are the same as these one used in the PA group. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements without shift. No compensation of movement is observed. After removing the prismatic glasses, the asked pointing movement to the targets is not shifted (No after-effects observed)
Study NCT02362607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Diabetes Management Protocol
Study NCT02362607 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Management Protocol
Study NCT02298244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV isolation + GP Ablation
Description: In real time builds the 3D card LA using nonfluoroscopic navigation system.Left and right PVs encircle in 1 lesion line by circumferential PV isolation.Radiofrequency energy delivered at 43◦C,35 W,0.5 cm away from the PV ostia at the anterior wall,and reduced to 43◦C,30 W,1 cm away from the PV ostia at the posterior wall,with a saline irrigation speed of 17 ml/min.Each lesion of ablation continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 seconds.The endpoint of circumferential PV isolation is PV isolation;this confirm when Lasso mapping show the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.To accomplish ganglionated plexi ablation,LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter HFS.Rectangular electrical stimuli were delivered at a frequency of 50 Hz,output amplitude 15V and pulse duration of 10 ms,for 5 sec
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Given PO
Study NCT01172301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential amino acid intake + Leucine vs total AA supplement
Description: 7 g as bolus
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib Hydrochloride
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography (ECHO)
Study NCT02037867 — intervention group
Intervention type: DEVICE
Intervention: Fibrosis Biomarkers
Description: Liver disease stratification with liver stiffness scan (Transient Elastography) Analysis of diagnostic performance of serum fibrosis markers (as listed above) Whole blood samples obtained for DNA analysis
Study NCT02298244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV isolation + GP ablation + Pulmonary GP ablation
Description: The procedure of AF ablation is the same like in the circumferential PV isolation + GP Ablation.~8-Fr sheath is carried through the right heart into the pulmonary artery trunk. Using ablation electrode constructed 3D map of the pulmonary artery trunk and the right and left main branches. Further HFS performed with the tip ablation electrode at the bifurcation of the pulmonary artery and in the ostium of the left and right pulmonary arteries (less than 2 mm distal to the bifurcation) 20 Hz, duration of each stimulus 10 ms. A positive response would be considered an increase in the RR interval of more than 50% of baseline within 10 seconds. In areas with a positive response to HFS, will be performed RFA Efficiency criterion: no previously described responses to HFS in the ablation area. Parameters RFA: 8-10 watts for 60 seconds duration at one point, the irrigation speed of 5 ml / min.
Study NCT02914626 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravitreal ranibizumab
Description: Intravitreal ranibizumab injection
Study NCT02914626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab
Description: Intravitreal ranibizumab injection
Study NCT00601718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO
Study NCT00601718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00601718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00601718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00601718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00601718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00601718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00601718 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT02968030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strength
Description: Strength training The strength training for lower limbs muscles occurred twice a week, 40 minutes per session for eight consecutive weeks.~n the first two weeks of training, each elderly performed the exercises with 50% of its load defined in 8RM test, increasing to 60 and 70% of the load in the third and fourth subsequent weeks, respectively. After this period, a new evaluation by 8RM strength test was conducted, adopting the fifth and sixth weeks of training 50% of value of the new load defined in 8RM test and to finalize the program in seventh and eighth weeks applied, respectively, 60% and 70% of the new charge. The exercises were performed for the quadriceps, hamstrings, muscles adductor and abductor hip.
Study NCT02669563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]4F-MHPG
Description: IV injection of \[18F\]4F-MHPG
Study NCT02669563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]3F-PHPG
Description: IV injection of \[18F\]3F-PHPG
Study NCT02669563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13N]ammonia
Description: IV injection of \[13N\]ammonia
Study NCT02669563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]HED
Description: IV injection of \[11C\]HED
Study NCT02985346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis
Study NCT02985346 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis
Study NCT00841724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine, Busulfan, Thymoglobuline
Study NCT02506777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Study NCT02506777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoruracil
Study NCT02506777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoruracil
Study NCT02506777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin